Prohemostatic Therapy: The Rise and Fall of Aprotinin

ABSTRACT

Aprotinin has been used clinically to enhance hemostasis for decades and was approved in the United States by the Food and Drug Administration in 1993 to reduce the transfusion requirement during coronary artery bypass surgery. Marketing of aprotinin ceased recently when observational studies and a randomized clinical trial reported increased cardiovascular toxicity in patients receiving this drug. The importance of prohemostatic therapy is reviewed in light of new information on long-term deleterious effects of blood transfusion, including increased risk of cardiovascular disease, malignancy, and infection possibly attributable to delivery of a load of red cell–derived redox-active iron. Weaknesses in design of clinical trials that failed to control adequately for such alternative mechanisms of toxicity complicate interpretation of risks versus benefits in clinical trials of aprotinin given to reduce transfusion requirement in the acute surgical setting. Properties and applications of aprotinin that may not have received sufficient attention in the decision to remove this drug from the therapeutic armamentarium are reviewed. Potential application of prohemostatic drugs, including aprotinin to special populations at risk for operative blood loss requiring transfusion, is illustrated by the description of nine patients with coagulopathies whose operative bleeding was managed effectively with aprotinin. This drug may remain safe and effective in patients at risk of bleeding with surgery. Beneficial effects of aprotinin seemingly unrelated to its prohemostatic properties, especially its apparent striking antineoplastic effects, warrant further study.

KEYWORDS

Aprotinin - blood transfusion - prohemostatic therapy - iron toxicity

REFERENCES

• 1 Mannucci P M, Levi M. Prevention and treatment of major blood loss.  N Engl J Med. 2007;  356(22) 2301-2311
• 2 Levy J H. Massive transfusion coagulopathy.  Semin Hematol. 2006;  43(suppl 1) S59-S63
• 3 Mahdy A M, Webster N R. Perioperative systemic haemostatic agents.  Br J Anaesth. 2004;  93(6) 842-858
• 4 Levi M, Vink R, de Jonge E. Management of bleeding disorders by prohemostatic therapy.  Int J Hematol. 2002;  76(suppl 2) 139-144
• 5 Segal H, Hunt B J. Aprotinin: pharmacological reduction of perioperative bleeding.  Lancet. 2000;  355 1289-1290
• 6 Jurlander B, Thim L, Klausen N K et al.. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development.  Semin Thromb Hemost. 2001;  27(4) 373-384
• 7 Hedner U. Mechanism of action of factor VIIa in the treatment of coagulopathies.  Semin Thromb Hemost. 2006;  32(suppl 1) 77-85
• 8 Sodha N, Boodhwani M, Bianchi C, Ramlawi B, Sellke F. Aprotinin in cardiac surgery.  Expert Rev Cardiovasc Ther. 2006;  4(2) 151-160
• 9 Ickx B, Van der Linden P, Melot C et al.. Comparison of the effects of aprotinin and tranexamic acid on blood loss and red blood cell transfusion requirements during the late stages of liver transplantation.  Transfusion. 2006;  46(4) 595-605
• 10 Shiga T, Wajima Z, Inoue T, Sakamoto A. Aprotinin in major orthopedic surgery: a systematic review of randomized controlled trials.  Anesth Analg. 2005;  101(6) 1602-1607
• 11 Stewart A, Newman L, Sneddon K, Harris M. Aprotinin reduces blood loss and the need for transfusion in orthognathic surgery.  Br J Oral Maxillofac Surg. 2001;  39(5) 365-370
• 12 Vaporciyan A A, Putnam Jr J B, Smythe W R. The potential role of aprotinin in perioperative management of malignant tumors.  J Am Coll Surg. 2004;  198(2) 266-278
• 13 Lamarra M, Azzu A A, Kulatilake E N. Cardiopulmonary bypass in the early puerperium: possible new role for aprotinin.  Ann Thorac Surg. 1992;  54(2) 361-363
• 14 Sher G. Trasylol in the management of abruptio placentae with consumption coagulopathy and uterine inertia.  J Reprod Med. 1980;  25(3) 113-118
• 15 Stroup J, Haraway D, Beal J M. Aprotinin in the management of coagulopathy associated with amniotic fluid embolus.  Pharmacotherapy. 2006;  26(5) 689-693
• 16 Joly L M, Sermet A, Turak B, Samama C M. Hemorragie massive après laminectomie dorsale décompressive [Massive haemorrhage after dorsal decompressive laminectomy] [in French].  Ann Fr Anesth Reanim. 2005;  24(10) 1278-1281
• 17 Palmer J D, Francis J L, Pickard J D, Ianottie F. The efficacy and safety of aprotinin during intracranial surgery.  J Neurosurg. 2003;  98(6) 1208-1216
• 18 van Oeveren W, Harder M P, Roozendaal K J, Eijsman L, Wildevuur C R. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass.  J Thorac Cardiovasc Surg. 1990;  99(5) 788-796
• 19 Boeken U, Litmathe J, Kurt M, Feindt P, Gams E. CABG-procedures in patients with pretreatment with the GPIIb/IIIa-receptor antagonist tirofiban (Aggrastat©): modification of perioperative management?.  Int J Cardiol. 2008;  127(2) 257-259
• 20 Ouattara A, Bouzguenda H, Le Manach Y, Léger P, Mercadier A, Leprince P. Impact of aspirin with or without clopidogrel on postoperative bleeding and blood transfusion in coronary surgical patients treated prophylactically with a low-dose of aprotinin.  Eur Heart J. 2007;  28(8) 1025-1032
• 21 Roath O S, Majer R V, Smith A G. The use of aprotinin in thrombocytopenic patients: a preliminary evaluation.  Blood Coagul Fibrinolysis. 1990;  1(2) 235-237
• 22 Bidstrup B P, Royston D, Taylor K M, Sapsford R N. Effect of aprotinin on need for blood transfusion in patients with septic endocarditis having open-heart surgery.  Lancet. 1988;  1(8581) 366-367
• 23 Mayer S A, Rincon F. Ultra-early hemostatic therapy for acute intracerebral hemorrhage.  Semin Hematol. 2006;  43(1, suppl 1) S70-S76
• 24 Vanek T, Jarez M, Fajt T et al.. Fibrinolytic inhibitors in off pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo).  Eur J Cardiothorac Surg. 2005;  28(4) 563-568
• 25 Beierlein W, Scheule A, Dietrich W, Ziemer G. Forty years of clinical aprotinin use: a review of 124 hypersensitivity reactions.  Ann Thorac Surg. 2005;  79(2) 741-748
• 26 Mahdy A M, Webster N R. Perioperative systemic haemostatic agents.  Br J Anaesth. 2004;  93(6) 842-858
• 27 Bayer Health Care Pharmaceuticals .Product information on Trasylol including warnings. Available at: http://www.trasylol.com/ Accessed December 1, 2009
• 28 Weber R S, Jabbour N, Martin R C. Anemia and transfusions in patients undergoing surgery for cancer.  Ann Surg Oncol. 2008;  15(1) 34-45
• 29 Hjalgrim H, Edren G, Rostgaard K et al.. Cancer incidence in blood transfusion recipients.  J Natl Cancer Inst. 2007;  99(24) 1864-1874
• 30 Murphy G J, Reeves B C, Rogers C A, Rizvi S I, Culliford L, Angelini G D. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery.  Circulation. 2007;  116(22) 2544-2552
• 31 Jani S M, Smith D E, Share D et al.. Blood transfusion and in-hospital outcomes in anemic patients with myocardial infarction undergoing percutaneous coronary intervention.  Clin Cardiol. 2007;  30(10, suppl 2) 1149-1156
• 32 Rao S V, Jollis J G, Harrington R A et al.. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes.  JAMA. 2004;  292(13) 1555-1562
• 33 Bilgin Y M, van de Watering L M, Eijsman L, Versteegh M I, van Oers M H, Brand A. Is increased mortality associated with post-operative infections after leukocytes containing red blood cell transfusions in cardiac surgery? An extended analysis.  Transfus Med. 2007;  17(4) 304-311
• 34 Abu-Rustum N R, Richard S, Wilton A et al.. Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survival.  Gynecol Oncol. 2005;  99(2) 320-326
• 35 Gangireddy C, Rectenwald J R, Upchurch G R et al.. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism.  J Vasc Surg. 2007;  45(2) 335-341 discussion 341-342
• 36 Nilsson K R, Berenholtz S M, Garrett-Mayer E, Dorman T, Klag M J, Pronovost P J. Association between venous thromboembolism and perioperative allogeneic transfusion.  Arch Surg. 2007;  142(2) 126-132
• 37 Yeh J J, Gonen M, Tomlinson J S, Idrees K, Brennan M F, Fong Y. Effect of blood transfusion on outcome after pancreaticoduodenectomy for exocrine tumour of the pancreas.  Br J Surg. 2007;  94(4) 466-472
• 38 Khorana A A, Francis C W, Blumberg N, Culakova E, Refaai M A, Lyman G H. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer.  Arch Intern Med. 2008;  168(21) 2377-2381
• 39 Landis R C, Asimakopoulos G, Poullis M, Haskard D O, Taylor K M. The antithrombotic and antiinflammatory mechanisms of action of aprotinin.  Ann Thorac Surg. 2001;  72(6) 2169-2175
• 40 Poston R S, White C, Gu J et al.. Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting.  Ann Thorac Surg. 2006;  81(1) 104-110
• 41 Chabbat J, Porte P, Tellier M, Steinbuch M. Aprotinin is a competitive inhibitor of the factor VIIa-tissue factor complex.  Thromb Res. 1993;  71(3) 205-215
• 42 Spannagl M, Dietrich W, Beck A, Schramm W. High dose aprotinin reduces prothrombin and fibrinogen conversion in patients undergoing extracorporeal circulation for myocardial revascularization.  Thromb Haemost. 1994;  72(1) 159-160
• 43 Desai P H, Kurian D, Thirumavalavan N et al.. A randomized clinical trial investigating the relationship between aprotinin and hypercoagulability in off-pump coronary surgery.  Anesth Analg. 2009;  109(5) 1387-1394
• 44 Bittner H, Richter M, Kuntze T et al.. Aprotinin decreases reperfusion injury and allograft dysfunction in clinical lung transplantation.  Eur J Cardiothorac Surg. 2006;  29(2) 210-215
• 45 Harmon D, Ghori K, Eustace N, O’Callaghan S, O’Donnell A, Shorten G. Aprotinin the incidence of cognitive deficit following CABG and cardiopulmonary bypass: a pilot randomized controlled study.  Can J Anaesth. 2004;  51(10) 1002-1009
• 46 Williams A, Gettinger A. Transfusion therapy in the intensive care unit.  Curr Opin Anaesthesiol. 2006;  19(2) 127-131
• 47 Fortenberry J D, Meier A H, Pettignano R, Heard M, Chambliss C R, Wulkan M. Extracorporeal life support for posttraumatic acute respiratory distress syndrome at a children’s medical center.  J Pediatr Surg. 2003;  38(8) 1221-1226
• 48 Latner A, Longstaff E, Turner G A. Anti-tumor activity of aprotinin.  Br J Cancer. 1974;  30(1) 60-67
• 49 Zacharski L R. Malignancy as a solid phase coagulopathy: implications for the etiology, pathogenesis and treatment of cancer.  Semin Thromb Hemost. 2003;  29(3) 239-246
• 50 Dunbar S D, Ornstein D L, Zacharski L R. Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin.  Expert Opin Investig Drugs. 2000;  9(9) 2085-2092
• 51 Lentschener C, Li H, Franco D et al.. Intraoperatively administered aprotinin increases one year survival after elective liver resection for colorectal metastasis.  Anesthesiology. 1998;  89(3A) A1186
• 52 Lentschener C, Li H, Franco D et al.. Intraoperatively-administered aprotinin and survival after elective liver resection for colorectal cancer metastasis. A preliminary study.  Fibrinolysis Proteolysis. 1999;  13(1) 39-45
• 53 Norman P H, Thall P F, Purugganan R V et al.. A possible association between aprotinin and improved survival after radical surgery for mesothelioma.  Cancer. 2009;  115(4) 833-841
• 54 Tucker T A, Dean C, Komissarov A et al.. The urokinase receptor supports tumorigenesis of human malignant pleural mesothelioma cells.  Am J Respir Cell Mol Biol. 2009;  , July 27 (Epub ahead of print)
• 55 Royston D, Bidstrup B P, Taylor K M, Sapsford R N. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery.  Lancet. 1987;  2(8571) 1289-1291
• 56 Beighton P, Solomon L, Soskolne C L. Articular mobility in an African population.  Ann Rheum Dis. 1973;  32(5) 413-418
• 57 Kinsler E L, Vande Vusse L K, Malone M G, Zacharski L R, Whiteside J L. Pelvic organ prolapse associated with hypermobility syndrome and operative bleeding managed with aprotinin.  J Pelvic Med Surg. 2008;  14(1) 65-68
• 58 Dirkmann D, Hanke A A, Görlinger K, Peters J. Perioperative use of modified thromboelastography in factor XI deficiency: a helpful method to assess drug effects.  Acta Anaesthesiol Scand. 2007;  51(5) 640-643
• 59 Eber W N. Massive blood transfusion in the elective surgical setting.  Transfus Apheresis Sci. 2002;  27(1) 83-92
• 60 Palanzo D A, Sadr F S. Coronary artery bypass grafting in a patient with haemophilia B.  Perfusion. 1995;  10(4) 265-270
• 61 Greaves M, Watson H G. Approach to the diagnosis and management of mild bleeding disorders.  J Thromb Haemost. 2007;  5(suppl 1) 167-174
• 62 Henry D A, Carless P A, Moxey A J et al.. Anti-fibrinolytic use for minimizing perioperative allogeneic blood transfusion.  Cochrane Database Syst Rev. 2007;  (4) CD001886
• 63 Karkouti K, Beattie W S. Propensity score case-control comparison of aprotinin and tranexamic acid in high transfusion-risk cardiac surgery.  Transfusion. 2006;  46(3) 327-338
• 64 Mangano D T, Tudor I C, Dietzel A C. The risk associated with aprotinin in cardiac surgery.  N Engl J Med. 2006;  354(4) 353-365
• 65 Mangano D T, Miao Y, Vuylsteke A et al.. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery.  JAMA. 2007;  297(5) 471-479
• 66 U.S. Food and Drug Administration .Aprotinin injection (marketed as Trasylol) information [updated May 14, 2008; cited May 29]. Available at: http://www.fda.gov/cder/drug/infopage/aprotinin/default.htm See also: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatients andProviders/ucm142720.htm Accessed November 27, 2009
• 67 Trasylol Public Health Advisory Update .Available at: http://factsandcomparisons.com/News/ArticlePage.aspx?id=7387 Accessed January 25, 2010
• 68 Sedrakyan A, Treasure T, Elefteriades J A. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials.  J Thorac Cardiovasc Surg. 2004;  128(3) 442-448
• 69 Brown J R, Birkmeyer N J, O’Connor G T. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery.  Circulation. 2007;  115(22) 2801-2813
• 70 Furnary A P, Wu Y, Hiratzka L F, Grunkemeier G L, Page III U S. Aprotinin does not increase the risk of renal failure in cardiac surgery patients.  Circulation. 2007;  116(11, suppl) 1127-1133
• 71 Rogers M A, Blumberg N, Saint S K, Kim C, Nallamothu B K, Langa K M. Allogeneic blood transfusions explain increased mortality in women after coronary artery bypass graft surgery.  Am Heart J. 2006;  152(6) 1028-1034
• 72 Koch C G, Li L, Duncan A I et al.. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting.  Crit Care Med. 2006;  34(6) 1608-1616
• 73 Madjdpour C, Heindl V, Spahn D R. Risks, benefits, alternatives and indications of allogeneic blood transfusions.  Minerva Anestesiol. 2006;  72(5) 283-298
• 74 Meyers D G, Jensen K C, Menitove J E. A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events.  Transfusion. 2002;  42(9) 1135-1139
• 75 Zacharski L R, Chow B K, Howes P S et al.. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease.  JAMA. 2007;  297(6) 603-610
• 76 Gupta A, Sharma S, Kaur I, Chopra K. Renoprotective effects of sesamol in ferric nitrilotriacetate-induced oxidative renal injury in rats.  Basic Clin Pharmacol Toxicol. 2009;  104(4) 316-321
• 77 Zhong Y, Onuki J, Yamasaki T, Ogawa O, Akatsuka S, Toyokuni S. Genome-wide analysis identifies a tumor suppressor role for aminoacylase 1 in iron-induced rat renal cell carcinoma.  Carcinogenesis. 2009;  30(1) 158-164
• 78 Levy J H. Aprotinin is useful as a hemostatic agent in cardiopulmonary surgery: yes.  J Thromb Haemost. 2006;  4(9) 1875-1878
• 79 Karkouti K, Beattie W S. Aprotinin is useful as a hemostatic agent in cardiopulmonary surgery: no.  J Thromb Haemost. 2006;  4(9) 1879-1881
• 80 Ferraris V A, Bridges C R, Anderson R P. Aprotinin in cardiac surgery.  N Engl J Med. 2006;  354(18) 1953-1957
• 81 Bridges C R. Valid comparisons of antifibrinolytic agents used in cardiac surgery.  Circulation. 2007;  115(22) 2790-2792
• 82 Ferguson Jr T B. Aprotinin—are there lessons learned?.  JAMA. 2007;  297(5) 527-529
• 83 Levy J H. Aprotinin versus tranexamic acid: the controversy continues.  Transfusion. 2006;  46(3) 319-320
• 84 Ray W A. Learning from aprotinin—mandatory trials of comparative efficacy and safety needed.  N Engl J Med. 2008;  358(8) 840-842
• 85 Schneeweiss S, Seeger J D, Landon J, Walker A M. Aprotinin during coronary-artery bypass grafting and risk of death.  N Engl J Med. 2008;  358(8) 771-783
• 86 Shaw A D, Stafford-Smith M, White W D et al.. The effect of aprotinin on outcome after coronary-artery bypass grafting.  N Engl J Med. 2008;  358(8) 784-793
• 87 Fergusson D A, Hebert P C, Mazer D et al.. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.  N Engl J Med. 2008;  358(22) 2319-2331
• 88 Murkin J M. Lessons learned in antifibrinolytic therapy: the BART trial.  Semin Cardiothorac Vasc Anesth. 2009;  13(2) 127-131
• 89 Ray W A, Stein C M. The aprotinin story—is BART the final chapter?.  N Engl J Med. 2008;  358(22) 2398-2400
• 90 Eser O, Kalkan E, Cosar M et al.. The effect of aprotinin on brain ischemic-reperfusion injury after hemorrhagic shock in rats: an experimental study.  J Trauma. 2007;  63(2) 373-378
• 91 Hruby Z, Wendycz D, Kopeć W, Zieliński B, Paczek L, Soin J. Mechanism of antinephritic effect of proteinase inhibitors in experimental anti-GBM glomerulopathy.  Res Exp Med (Berl). 2000;  199(5) 295-307
• 92 Dietrich W, Busley R, Boulesteix A L. Effects of aprotinin dosage on renal function: an analysis of 8,548 cardiac surgical patients treated with different dosages of aprotinin.  Anesthesiology. 2008;  108(2) 189-198
• 93 Backer C L, Kelle A M, Stewart R D et al.. Aprotinin is safe in pediatric patients undergoing cardiac surgery.  J Thorac Cardiovasc Surg. 2007;  134(6) 1421-1426
• 94 Stamou S C, Reames M K, Skipper E et al.. Aprotinin in cardiac surgery patients: is the risk worth the benefit?.  Eur J Cardiothorac Surg. 2009;  36(5) 869-875
• 95 Inamura Y, Miyamae M, Sugioka S et al.. Aprotinin abolishes sevoflurane postconditioning by inhibiting nitric oxide production and phosphorylation of protein kinase C-delta and glycogen synthase kinase 3beta.  Anesthesiology. 2009;  111(5) 1036-1043
• 96 Jakobsen C J, Søndergaard F, Hjortdal V E, Johnsen S P. Use of aprotinin in cardiac surgery: effectiveness and safety in a population-based study.  Eur J Cardiothorac Surg. 2009;  36(5) 863-868
• 97 Reeves B C, Murphy G J, Rogers C A, Culliford L, Rizvi S I, Angelini G D. Response to letter regarding article, “Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery”.  Circulation. 2008;  117(25) e507
• 98 Ishibashi N, Iwata Y, Zurakowski D, Lidov H G, Jonas R A. Aprotinin protects the cerebral microcirculation during cardiopulmonary bypass.  Perfusion. 2009;  24(2) 99-105
• 99 Nicolau-Raducu R, Subramaniam K, Marquez J, Wells C, Hilmi I, Sullivan E. Safety and efficacy of tranexamic acid compared with aprotinin in thoracic aortic surgery with deep hypothermic circulatory arrest.  J Cardiothorac Vasc Anesth. 2010;  24(1) 73-79
• 100 Wang X, Zheng Z, Ao H et al.. A comparison before and after aprotinin was suspended in cardiac surgery: different results in the real world from a single cardiac center in China.  J Thorac Cardiovasc Surg. 2009;  138(4) 897-903
• 101 Ramlawi B, Otu H, Russo M J, Novick R J, Bianchi C, Sellke F W. Aprotinin attenuates genomic expression variability following cardiac surgery.  J Card Surg. 2009;  24(6) 772-780
• 102 Choi H C, Lee K Y, Lee D H, Kang Y J. Heme oxygenase-1 induced by aprotinin inhibits vascular smooth muscle cell proliferation through cell cycle arrest in hypertensive rats.  Korean J Physiol Pharmacol. 2009;  13(4) 309-313
• 103 Zacharski L R, Chow B K, Howes P S et al.. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial.  J Natl Cancer Inst. 2008;  100(14) 996-1002
• 104 Spinella P C, Perkins J G, McLaughlin D F et al.. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion.  J Trauma. 2008;  64(2) 286-293
• 105 Holt R L, Martin T D, Hess P J, Beaver T M, Klodell C T. Jehovah’s Witnesses requiring complex urgent cardiothoracic surgery.  Ann Thorac Surg. 2004;  78(2) 695-697
• 106 Aprotinin US Special Access Protocol .Available at: http://clinicaltrials.gov/ct2/show/NCT00611845 Expanded access is currently available for this treatment. Verified by Bayer, September 2009. First received January 29, 2008; last updated September 28, 2009
• 107 Society of Cardiovascular Anesthesiologists .PRO: Aprotinin use is justified in all high-risk cardiac surgery. Available at: http://www.scahq.org/sca3/newsletters/oct_pro.shtml Accessed December 1, 2009